Eli Lily to Acquire Disarm Therapeutics for ~$1.36B

 Eli Lily to Acquire Disarm Therapeutics for ~$1.36B

Eli Lily to Acquire Disarm Therapeutics for ~$1.36B

Shots:

  • Lilly to acquire Disarm for $135M upfront and ~$1.225B as potential development regulatory and commercial milestones, making a total deal value of ~1.36B
  • The acquisition will expand Lilly’s R&D efforts in pain and neurodegeneration with the addition of Disarm’s preclinical SARM1 programs for axonal degeneration
  • Disarm is advancing its potent SARM1 inhibitors in preclinical development intending to deliver patients with peripheral neuropathy and other neurological diseases like ALS and MS

    Click here ­to­ read full press release/ article | Ref: Eli Lilly | Image: Eli Lilly

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post